← Back to Search
Blood Pressure Management
Blood Pressure Control for Stroke (ENCHANTED3/MT Trial)
Sydney, Australia
N/A
Recruiting
Led By Craig Anderson, PhD
Research Sponsored by The George Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age ≥18 years;
Use of endovascular therapy (EVT) within 24 hours of symptom onset or last known well according to local guidelines;
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24-48 hours
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to study the effects of different approaches to managing high blood pressure in patients who have had a stroke. The study will include up to 2,000 patients with high blood pressure after a
Who is the study for?
This trial is for adults over 18 who've had a stroke treated with endovascular therapy (EVT) within the last day and have high blood pressure (BP ≥150 mmHg). They must not have other conditions that would exclude them from the study.
What is being tested?
The trial is testing three ways to manage high blood pressure after EVT for stroke: conservative control, moderate control, and intensive control. Patients will be randomly assigned in equal numbers to one of these strategies to find the best BP management approach.
What are the potential side effects?
Potential side effects may include changes in kidney function, dizziness or fainting due to low blood pressure, and possible increased risk of further strokes or heart issues depending on how much the BP is lowered.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
I received a special blood vessel procedure within 24 hours of my symptoms starting.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24-48 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24-48 hours
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
modified Rankin scale
Secondary study objectives
Any intracranial haemorrhage (ICH)
Excellent functional neurological outcome
Health Related Quality of Life
+6 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Group I: Moderate SBP ControlExperimental Treatment1 Intervention
Group II: Intensive SBP ControlExperimental Treatment1 Intervention
Group III: Conservative SBP ControlExperimental Treatment1 Intervention
Find a Location
Closest Location:University of Calgary· Calgary, Canada· 1633 miles
Who is running the clinical trial?
The George InstituteLead Sponsor
83 Previous Clinical Trials
272,508 Total Patients Enrolled
13 Trials studying Stroke
68,110 Patients Enrolled for Stroke
University of CalgaryOTHER
825 Previous Clinical Trials
899,586 Total Patients Enrolled
36 Trials studying Stroke
40,945 Patients Enrolled for Stroke
Changhai HospitalOTHER
416 Previous Clinical Trials
551,270 Total Patients Enrolled
12 Trials studying Stroke
115,101 Patients Enrolled for Stroke
Craig Anderson, PhDPrincipal InvestigatorThe George Institute
3 Previous Clinical Trials
3,625 Total Patients Enrolled
3 Trials studying Stroke
3,625 Patients Enrolled for Stroke